The American journal of tropical medicine and hygiene
-
Am. J. Trop. Med. Hyg. · Mar 1977
Mebendazole in the treatment of severe symptomatic trichuriasis in children.
Mebendazole (methyl-5-benzoylbenzimidazole-2-carbamate), a new broad spectrum anthelmintic, cured 26 (74% out of 35 children) with severe symptomatic trichuriasis. Repeat course of therapy were necessary in some cases. The nine treatment failures all showed large reductions (82-99%) in egg counts. ⋯ In the recommended dosage of 100 mg twice daily for 3 days mebendazole failed to achieve a cure rate of 95% to 100% reported in asymptomatic individuals and those with light infections of Trichuris trichiura. It is probable that measures to control diarrhea before administering mebendazole in an increased, extended, or repreated dosage schedule will achieve a higher cure rate. The drug was well tolerated and completely free from any toxic effects.
-
Am. J. Trop. Med. Hyg. · Nov 1976
Human babesiosis on Nantucket Island: transmission by nymphal Ixodes ticks.
In order to identify potential vectors of human babesiosis (Babesia microli) in southern Massachusetts, I attempted to transmit the infection via nymphal ticks of that species found to be most abundant on reservoir hosts (Peromyscus leucopus) in nature. Mice were collected at frequent intervals throughout a year in a known enzootic focus on Nantucket Island, and ticks were removed by hand. Ticks of only two species were present; larvae and nymphs of Ixodes scapularis were about 10 times as numerous as were those of Dermacentor variabilis. ⋯ Nymphs reared from larvae that had attached to a non-infected hamster did not transmit babesiosis to other hamsters. These results suggest that I. scapularis serves as a vector of babesios-s on Nantucket hamsters. These results suggest that I. scapularis serves as a vector of babesiosis on Nantucket Island.
-
Am. J. Trop. Med. Hyg. · May 1975
Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites.
With strict adherence to ethical guidelines, a volunteer was immunized against sporozoites of Plasmodium falciparum and P. vivax, the antigen consisting of attenuated sporozoites of each species inoculated through bites of mosquitoes X-irradiated at a minimum dosage of 15,000 rads. On one occasion this dosage did not render all P. vivax sporozoites noninfective. ⋯ Once immunized, the volunteer was protected for not more than 3 months and 6 months, respectively, from infective P. falciparum and P. vivax sporozoites, the duration of protection being reflected by a positive species-specific circumsporozoite reaction. Studies in this volunteer, and in two others immunized with P. falciparum sporozoites, did not reveal any increase in serum levels of immunoglobulins G and M.
-
Am. J. Trop. Med. Hyg. · Sep 1974
Randomized Controlled Trial Comparative Study Clinical TrialDouble blind study with a new nitroimidazole derivative, Ro 7-0207, versus metronidazole in symptomatic intestinal amebiasis.
Of 115 patients with symptomatic intestinal amebiasis, 56 were treated with Ro 7-0207 and 59 with metronidazole in a double blind study. Results of treatment were similar in the two groups and side effects were of low intensity except in one patient who received Ro 7-0207 and developed numbness of hands and tongue, difficulty in speaking, and headache. These symptoms disappeared after termination of treatment.
-
Am. J. Trop. Med. Hyg. · Sep 1974
Two-year follow-up of hycanthone-treated schistosomiasis mansoni patients in St. Lucia.
Of 433 schistosomiasis mansoni patients in St. Lucia who were treated with hycanthone (3 mg/kg of body weight), 190 were seen 2 years after treatment and 143 of these had attended all follow-up examinations at 6 weeks, 6 months, 1 year and 2 years. Viable eggs were not detected in 86% at 1 year nor in 76% at 2 years. ⋯ Extremely high total reduction in egg excretion (98%) was achieved through 1 year, and even with reinfections this fell only to 87% at 2 years. Liver and spleen enlargement was related to intensity of infection and responded to treatment in 92% and 83% of instances, respectively. Among patients with hepatosplenomegaly, those 15 years or older showed less clinical response than younger patients but were too few for statistical comparison.